Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Humans
  • Myeloproliferative Disorders*
  • Nitriles
  • Pyrazoles / therapeutic use
  • Pyrimidines

Substances

  • ruxolitinib
  • Nitriles
  • Pyrimidines
  • Pyrazoles